These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36836123)

  • 1. Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis.
    Sun W; Wu Y; Ma F; Fan J; Qiao Y
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for
    Zhang M; Yu X; Wang J; Li Y; Cao L
    J Cancer Res Ther; 2021 Dec; 17(7):1672-1678. PubMed ID: 35381738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP Inhibitors for the Treatment of BRCA1/2-Mutated Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
    Kunwor R; Silver DP; Abu-Khalaf M
    Hematol Oncol Stem Cell Ther; 2023 Apr; 16(3):186-196. PubMed ID: 37023220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-agent PARP inhibitors for the treatment of patients with
    Poggio F; Bruzzone M; Ceppi M; Conte B; Martel S; Maurer C; Tagliamento M; Viglietti G; Del Mastro L; de Azambuja E; Lambertini M
    ESMO Open; 2018; 3(4):e000361. PubMed ID: 29942664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis.
    Caramelo O; Silva C; Caramelo F; Frutuoso C; Pinto L; Almeida-Santos T
    Hered Cancer Clin Pract; 2022 Sep; 20(1):34. PubMed ID: 36085046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
    Wang H; Wu M; Liu H; Zhou H; Zhao Y; Geng Y; Jiang B; Zhang K; Zhang B; Han Z; Du X
    Front Oncol; 2021; 11():785102. PubMed ID: 34900739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect and Safety of Therapeutic Regimens for Patients With Germline BRCA Mutation-Associated Breast Cancer: A Network Meta-Analysis.
    Jiang Y; Meng XY; Deng NN; Meng C; Li LH; He ZK; Wang XY; Song ZY; Cui RJ
    Front Oncol; 2021; 11():718761. PubMed ID: 34490117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer.
    Nicoletto MO; Baldoni A; Cavallin F; Grego A; Falci C; Nardin M; Mammano E; Lai E; Torri V
    Ther Adv Med Oncol; 2023; 15():17588359231173181. PubMed ID: 37360767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging therapeutic modalities of PARP inhibitors in breast cancer.
    Wang X; Shi Y; Huang D; Guan X
    Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis.
    Chang XF; Ren XL; Yang JQ; Shi JJ; Bai JH; Cui MS; Dong WW
    Breast; 2021 Oct; 59():44-50. PubMed ID: 34130011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer.
    Bustos MA; Yokoe T; Shoji Y; Kobayashi Y; Mizuno S; Murakami T; Zhang X; Sekhar SC; Kim S; Ryu S; Knarr M; Vasilev SA; DiFeo A; Drapkin R; Hoon DSB
    Cell Biosci; 2023 Nov; 13(1):200. PubMed ID: 37932806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer.
    Desnoyers A; Nadler M; Wilson BE; Stajer S; Amir E
    NPJ Breast Cancer; 2022 Mar; 8(1):43. PubMed ID: 35361769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of PARP inhibitors in the treatment of BRCA-mutated breast cancer: an updated systematic review and meta-analysis of randomized controlled trials.
    Sun X; Xu S; Li Y; Lv X; Wei M; He M
    Expert Rev Clin Pharmacol; 2023 Mar; 16(3):245-256. PubMed ID: 36908219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
    Bartoletti M; Pelizzari G; Gerratana L; Bortot L; Lombardi D; Nicoloso M; Scalone S; Giorda G; Baldassarre G; Sorio R; Puglisi F
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
    Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
    Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis.
    Gulia S; Kannan S; Ghosh J; Rath S; Maheshwari A; Gupta S
    ESMO Open; 2022 Oct; 7(5):100558. PubMed ID: 36007449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
    Schettini F; Giudici F; Bernocchi O; Sirico M; Corona SP; Giuliano M; Locci M; Paris I; Scambia G; De Placido S; Rescigno P; Prat A; Curigliano G; Generali D
    Eur J Cancer; 2021 May; 149():134-152. PubMed ID: 33862496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
    Tomao F; Bardhi E; Di Pinto A; Sassu CM; Biagioli E; Petrella MC; Palaia I; Muzii L; Colombo N; Panici PB
    Cancer Treat Rev; 2019 Nov; 80():101909. PubMed ID: 31629204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.
    Rose PG; Yao M; Chambers LM; Mahdi H; DeBernardo R; Michener CM; AlHilli M; Ricci S; Vargas R
    Anticancer Drugs; 2021 Nov; 32(10):1086-1092. PubMed ID: 34520432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal first-line treatment for platinum-eligible metastatic urothelial carcinoma: Comparison of chemo-immunotherapy, immunotherapy, and chemotherapy- A systematic review and meta-analysis.
    Li H; Ni M; Xue C; Li L; Huang R; Yang W; Hu A; An X; Shi Y
    Clin Immunol; 2022 Mar; 236():108927. PubMed ID: 35031491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.